Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saruparib + Camizestrant or ET vs CDK4/6i + ET or Camizestrant in Advanced Breast Cancer
NCT06380751Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of saruparib, camizestrant in breast cancer, sponsored by AstraZeneca. Started Aug 2024; status: recruiting.
02
Drugs
saruparibcamizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06380751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06380751.